療程功效
即時填充面部凹陷
填補皺紋細紋
長效補濕
改善鼻型
豐盈嘴唇
精準填充拉提 締造面部雕塑藝術
Filling & Lifting
Juvéderm®當中的透明質酸成份自然存在於人體，可被身體自然分解。而Juvéderm®利用獨家VYCROS™交聯鏈結科技，更可使療程效果更加自然和持久，配合Lidocaine利多卡因減痛成份，令療程更舒適放心。五個不同系列產品針對面部不同部位問題，配合獨特的MD CODES定點提昇打法，增強韌帶提肌力量，優化和鞏固臉部輪廓，從肌底結構做好強力承托，做到真正的逆齡！
Juvéderm®為您的面部即時注入強大的支撐力，解決因面部骨骼和脂肪的流失而造成的凹陷下垂沒有彈性的問題。重塑臉部輪廓，為您締造面部雕塑藝術，從此拒絕倦容！
效果見證
選擇Juvéderm®️的原因
獲歐盟CE及美國FDA認證，安全可靠
專利技術VYCROSS™交聯鏈結科技，能與肌膚自然融為一體，療程效果即時而持久
內含Lidocaine利多卡因減痛成份，令療程更舒適放心
成份自然，透明質酸自然存在於人體，能被身體自然分解
五個系列，針對面部不同需求
VOLUX™ 透明質酸濃度：25mg/ml
提供強力支撐度，適合用於下巴、下顎線。重新定義下巴美學，締造完美V面。
VOLUMA®️ 透明質酸濃度：20mg/ml
適合用於太陽穴、蘋果肌。中面立體拉提，顯著提昇中面輪廓。
VOLIFT®️ 透明質酸濃度：17.5mg/ml
適合用於面部較多表情的位置，額頭，眉部，臉頰，法令紋，木偶紋。自然豐盈，緊致淡紋。
VOBELLA®️ 透明質酸濃度：15mg/ml
適合用於修飾細紋，改善淚溝及淚溝型黑眼圈。重拾耀眼明眸。
VOLITE™ 透明質酸濃度：12mg/ml
適合用於全面，頸部，胸口位置及雙手。一次療程注入長效深層水嫩，改善膚質，補濕提亮回彈，從肌底煥發自然緊緻彈滑肌。
“美感密碼”療程三部曲
Step1： 基礎提昇療程 Foundation
中面立體拉提 以提昇中面輪廓開始，豐盈蘋果肌，太陽穴，修復輪廓下垂。
Step2：立體輪廓療程 Contouring
調整臉型至黃金比例 改善下巴及下顎線線條，調整臉部整體比例，重新輪廓立體感。
Step3：進階微調療程 Refinement
精雕細緻部位 改善臉部微小細節，緊緻淡紋，力臻完美臉容。
安心承諾
原廠認可的醫療中心
原廠正版正貨保證
專業醫療團隊主理
受醫療集團監察
絕不硬銷，無額外隱藏收費
行內超過12年實踐經驗
原理及技術
FAQ
**療程效果因人而異，以上資料和相片由廠商提供，只供參考* *
Allergan. Unpublished Data. REF-74203. Juvéderm®, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019. References: 1. De Maio, M. Aesthetic Plast Surg. 2021 Apr;45(2):690-709; 2. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e; 3. De Maio M, et al. Plast Reconstr Surg. 2017 Oct;140(4):540e-550e; 4. De Maio M. et. al. Plast Reconstr Surg. 2017 Sep;140(3):393e-404e; 5. Ogilvie P et al. J Cosmetic Dermatol. 2019;00:1-6; 6. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81-9; 7. Allergan. Data on File. REF-96563. FILLERS GLOBAL NUMBER OF SYRINGES. May 2022. 100 million Juvederm® syringes manufactured worldwide from 2004 to April 2022; 8. VOLUX™, VOLUMA®, VOLIFT®, VOLBELLA® 及 VOLITE™ 均獲得歐盟 CE 認證. European Commission, Juvéderm hyaluronic acid based medical devices. EC certificate number: 3824296CE02; 3824296CE05; 3824296CE06; 3824296CE08; 3824296CE09, Aug 2019; 9. VOLUX™, VOLUMA®, VOLIFT® 及 VOLBELLA® (approval as VOLUX™ XC, VOLUMA® XC, VOLLURE® XC and VOLBELLA® XC in US) 均獲得美國 FDA 認證. U.S. Food and Drug Administration, Department of Health & Human Services. Juvéderm VOLUX XC approval letter P110033/S065, July 2022; Juvéderm VOLUMA XC approval letter P110033/S047, Jun 2020; Juvéderm VOLLURE XC approval letter P110033/S020, Mar 2017; Juvéderm VOLBELLA XC approval letter P110033/S053, May 2021; 10. Papakonstantinou E., et al. Dermatoendocrinol. 2012 Jul 1;4(3):253–258; 11. Tan KS, Oh SR, Priel A, Korn BS, Kikkawa DO (2011). Surgical Anatomy of the Forehead, Eyelids, and Midface for the Aesthetic Surgeon. In Master Techniques in Blepharoplasty and Periorbital Rejuvenation. (pp.11-24). Springer; 12. Mariwalla K. (2011). Rejuvenation of the Upper Face. Medscape Education; 13. Shin JW et al. Int. J. Mol. Sci. 2019,20(9),2126; 14. Niforos F et al. Clin Cosmet Investig Dermatol. 2019;12:791–98; 15. Allergan. Data On File. REF-80724. Juvéderm® VOLITE laboratory testing – immunohistochemistry; 16. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139–48; 17. Allergan. Unpublished Data. INT-JUV-1950127. VYCROSS® – longest duration of hyaluronic acid facial filler in clinical trials. Jan 2020; 18. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12. 19. Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15; 20. Dayan S et al. Aesthet Surg J. 2020 Jun 15;40(7):767-777; 21. Ogilvie P et al. Aesthet Surg J. 2020 Aug 14;40(9):NP499-NP510; 22. Lebreton P. 2004. WO2004092222A2. Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained; 23. De Maio M. Aesthetic Plast Surg. 2004;28:295-300; 24. Allergan. Unpublished Data. REF-80819. Juvéderm® is available in over 110 territories worldwide. Feb 2019; 25. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e; 26. Ogilvie P et al. Aesthet Surg J. 2020 Aug 14;40(9):NP499-NP510; 27: Beer K., et al. Dermatol Surg. 2021. 47(1), 80–85; 28. Ogilvie P et al. Dermatol Surg. 2020 Mar;46(3):376-385; 29. Ecclestron D, Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167-72; 30. Niforos F et al. Dermatol Surg. 2017;43(10):1271–80; 31. De Maio et. al., Plast Reconstr Surg, 2015 & 2017; 32. Signorini M et al. Plast Reconstr Surg. 2016 Jun;137(6):961e-71e; 33. Urdiales-Galvez F et al. Aesthetic Plast Surg. 2018 Apr;42(2):498-510; 34. Urdiales-Galvez F et al. Aesthetic Plast Surg. 2017 Jun;41(3):667-677; 35. de Almeida AT et al. Surg Cosmet Dermatol 2017;9(3):204-13. 36. Philipp-Dormston WG et al. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1088-1095; 37. Funt D & Pavicic T. Plast Surg Nurs. 2015 Jan-Mar;35(1):13-32; 38. Shah NS et al. J Am Acad Dermatol. 2002 Aug;47(2):241-4; 39. Fitzgerald R et al. Facial Plast Surg. 2016 Oct;32(5):532-55.
